Cialis (Tadalafil) Appetite & Cravings Changes: What the Evidence Actually Shows

What Tadalafil Actually Does in the Body

Tadalafil selectively inhibits phosphodiesterase type 5 (PDE5), preventing the breakdown of cyclic guanosine monophosphate (cGMP) in smooth muscle cells. The result is smooth-muscle relaxation and vasodilation, which underlies its efficacy in erectile dysfunction, lower urinary tract symptoms from benign prostatic hyperplasia, and pulmonary arterial hypertension [1].

PDE5 Expression and the Gut

PDE5 is expressed in the gastrointestinal tract, including the smooth muscle of the colon and the vasculature supplying the gut [2]. This anatomical fact prompts a reasonable question: could inhibiting PDE5 in gut tissue alter motility, gastric emptying, or appetite signaling?

Laboratory data confirm that cGMP signaling participates in regulating intestinal smooth muscle tone. One in-vitro study demonstrated tadalafil-induced relaxation of rat distal colon muscle strips [3]. However, relaxation of colonic smooth muscle is not the same as a change in appetite. Appetite regulation originates primarily in hypothalamic nuclei (arcuate, paraventricular, lateral hypothalamic area) and gut-derived peptide signals including ghrelin, GLP-1, peptide YY, and cholecystokinin [4]. None of these pathways are direct targets of PDE5 inhibition at therapeutic concentrations.

The Nitric-Oxide Connection

Tadalafil acts downstream of nitric oxide (NO). NO donors and cGMP have been studied for their influence on hypothalamic appetite circuits in animal models. A 2010 rodent study found that intracerebroventricular administration of an NO donor reduced food intake [5]. The relevant distinction is route and concentration: systemic oral tadalafil does not produce meaningful central nervous system cGMP changes at clinical doses, given limited CNS penetration and the blood-brain barrier.

Clinical Trial Data: Adverse Events Including GI Effects

The most rigorous source for tadalafil's side-effect profile is the FDA-approved prescribing information, which aggregates data from over 9,000 patients exposed in placebo-controlled trials [1].

The Brock et al. Trial (J Urol 2002)

Brock et al. Published one of the key early randomized trials establishing tadalafil's efficacy and tolerability profile. In a 12-week, double-blind, placebo-controlled study (N=348 men with erectile dysfunction), tadalafil 10 mg and 20 mg produced statistically significant improvements in erectile function domain scores compared to placebo (P<0.001) [6]. The adverse-event table in that publication lists dyspepsia, back pain, myalgia, nasal congestion, and flushing as the most common treatment-emergent events. Appetite change does not appear in the adverse-event data at either dose [6].

Dyspepsia occurred in approximately 10% of participants receiving tadalafil 20 mg vs. 1% placebo in that cohort [6]. Dyspepsia can cause postprandial discomfort that patients sometimes describe as reduced desire to eat, but this is mechanistically different from true anorexia driven by hypothalamic or hormonal changes.

FDA Prescribing Information Summary

The FDA label for Cialis (tadalafil) 10 mg and 20 mg as-needed dosing documents the following GI-related adverse reactions occurring in at least 2% of patients and more frequently than placebo [1]:

• Dyspepsia: 10 to 13% (dose-dependent)
• Nausea: approximately 3%
• Diarrhea: approximately 3%

Decreased appetite, anorexia, or food-craving alterations are absent from the adverse-reaction tables at any dose or indication [1]. The label for the 2.5 mg and 5 mg once-daily formulations used in BPH and daily-use ED shows a similar GI profile at lower incidence, with dyspepsia around 4% at 5 mg [1].

Pulmonary Arterial Hypertension Data (Adcirca 40 mg)

At the much higher 40 mg daily dose approved for pulmonary arterial hypertension under the brand name Adcirca, the adverse-event profile expands. The PHIRST trial (N=405) reported nausea in 11% of patients on tadalafil 40 mg vs. 8% placebo, and flushing, headache, and myalgia at higher rates than at ED doses [7]. Even at this supratherapeutic-for-ED dose, the published adverse-event table does not list appetite suppression as a distinct finding [7]. Nausea at 11% could transiently reduce caloric intake in some patients, but no PHIRST sub-analysis quantified energy intake or body weight as a primary or secondary endpoint.

Why Patients Report Appetite Changes Anecdotally

Post-Market Reports vs. RCT Data

A gap exists between what patients report on forums and what randomized trial data record. The FDA Adverse Event Reporting System (FAERS) is a passive surveillance database and cannot establish causation. Searches of FAERS for tadalafil show scattered reports of decreased appetite, but these reports lack denominator data, cannot distinguish confounding medications, and do not meet the threshold for a labeled adverse event [8].

Confounding Variables

Men taking tadalafil for BPH are frequently over age 50, on multiple medications including alpha-blockers, 5-alpha-reductase inhibitors (finasteride, dutasteride), and antihypertensives, all of which carry their own GI side-effect profiles [9]. Finasteride, for example, has been reported to cause decreased libido and mood changes that could secondarily affect appetite in a subset of users [10]. Attributing appetite change to tadalafil in a polypharmacy patient requires systematic medication review.

Dyspepsia Misclassified as Appetite Loss

Acid reflux and epigastric discomfort caused by tadalafil-related smooth-muscle relaxation of the lower esophageal sphincter may make patients less motivated to eat, particularly in the 4 to 6 hours after dosing. This is not appetite suppression in the endocrinologic sense. It is pain-mediated avoidance of eating. The distinction matters clinically because proton-pump inhibitors or H2 blockers can resolve the symptom without discontinuing tadalafil.

Tadalafil vs. Other PDE5 Inhibitors: GI Profile Comparison

The table below compares published GI adverse-event rates across the three most widely prescribed PDE5 inhibitors. Data are drawn from FDA prescribing information and published head-to-head data where available.

| Drug | Dyspepsia Rate | Nausea Rate | Half-Life | Appetite Listed as AE | |---|---|---|---|---| | Tadalafil (Cialis) 20 mg PRN | ~10 to 13% | ~3% | ~17.5 h | No | | Sildenafil (Viagra) 50 to 100 mg PRN | ~7% | ~3% | ~4 h | No | | Vardenafil (Levitra) 10 to 20 mg PRN | ~4% | <2% | ~4 to 5 h | No |

Sources: FDA prescribing information for Cialis [1], Viagra [11], and Levitra [12].

Tadalafil's higher dyspepsia rate relative to vardenafil may reflect its longer half-life and sustained smooth-muscle relaxation at the gastroesophageal junction. Sildenafil falls between the two. None of the three drugs list appetite change as a recognized adverse event in their FDA labels [1, 11, 12].

The Testosterone Interaction Question

Men with erectile dysfunction frequently have comorbid hypogonadism. Low testosterone is independently associated with reduced appetite in some studies and with increased appetite (and adiposity) in others, depending on severity [13]. A man who begins tadalafil while also starting testosterone replacement therapy may experience appetite changes attributable to testosterone-driven anabolic signaling rather than to the PDE5 inhibitor. Clinicians should document baseline appetite status before initiating either agent.

GLP-1 Co-prescribing and Appetite Attribution

An increasing number of men receive tadalafil alongside semaglutide or tirzepatide for concurrent obesity and ED management. In STEP-1 (N=1,961), semaglutide 2.4 mg produced 14.9% mean body-weight loss at 68 weeks versus 2.4% with placebo, driven substantially by appetite suppression and reduced food-reward signaling [14]. When a patient on both agents reports appetite loss, the GLP-1 receptor agonist is the pharmacologically plausible driver. Tadalafil should not receive the attribution without ruling out the more powerful appetite-modifying agent first.

BPH Indication and Daily Dosing: Does Duration of Exposure Matter?

Tadalafil 5 mg once daily is FDA-approved for the signs and symptoms of BPH. Long-term exposure data come primarily from open-label extension studies lasting up to 24 months. In the Porst et al. 24-month open-label extension of the LVHJ trial, safety data on over 500 men showed no emergent appetite-related adverse events after prolonged daily exposure [15]. This matters because some drug effects are dose-accumulation phenomena that only manifest with chronic use.

Once-Daily vs. As-Needed Dosing

At steady state, tadalafil 5 mg daily produces plasma trough concentrations roughly equivalent to the Cmax of a 10 mg as-needed dose divided across the dosing interval. This sustained low-level exposure does not appear to produce cumulative GI burden beyond what is seen acutely. The 5 mg prescribing information documents a lower dyspepsia rate (approximately 4%) than the 20 mg as-needed formulation [1], consistent with a dose-response relationship for dyspepsia rather than a chronic exposure effect.

What to Do if You Experience Appetite Changes on Tadalafil

Step One: Characterize the Symptom

Is the patient experiencing true loss of hunger cues, or is postprandial discomfort making eating aversive? A simple question clarifies this: "Do you feel hungry but avoid eating because it causes pain afterward?" If yes, the issue is likely dyspepsia. "Do you simply not feel hungry?" points toward a systemic cause requiring broader workup.

Step Two: Medication Review

List every drug, supplement, and OTC product the patient takes. Alpha-blockers (tamsulosin, alfuzosin), 5-alpha-reductase inhibitors, antidepressants, and opioids all affect GI motility or appetite signaling [9, 16]. Metformin, used frequently in the metabolic-syndrome population that overlaps with BPH and ED, causes nausea and anorexia in approximately 5 to 10% of users, especially in the first weeks of therapy [17].

Step Three: Laboratory Assessment

Check a comprehensive metabolic panel, thyroid-stimulating hormone, and total/free testosterone. Hypothyroidism, hepatic disease, and hypogonadism all reduce appetite independently and are more prevalent in the demographic that uses tadalafil [13, 18]. If laboratory results are normal and medication review is unrevealing, a brief structured food diary over 7 days provides objective caloric-intake data.

Step Four: Dose Adjustment Trial

If dyspepsia is the suspected mechanism, a supervised trial of reducing the tadalafil dose (e.g., from 20 mg to 10 mg PRN, or from 5 mg daily to 2.5 mg daily) may resolve GI symptoms while preserving therapeutic efficacy. Brock et al. Demonstrated that 10 mg tadalafil retained statistically significant improvements over placebo in IIEF erectile function domain scores, offering a clinically viable lower-dose option [6].

Clinician Perspective: When Appetite Change Should Prompt Further Evaluation

The American Urological Association (AUA) 2018 guideline on erectile dysfunction states that PDE5 inhibitors "are generally well tolerated" and that "serious adverse events are rare" [19]. The guideline does not list appetite disturbance as a monitoring target during PDE5 inhibitor therapy.

Appetite loss lasting more than two weeks, accompanied by unintentional weight loss exceeding 5% of body weight, or concurrent systemic symptoms (fatigue, night sweats, change in bowel habits) warrants evaluation independent of tadalafil use. The American Cancer Society recommends evaluation for unexplained weight loss exceeding 10 pounds (4.5 kg) as a possible early cancer signal [20]. Attributing such findings to a PDE5 inhibitor without workup risks diagnostic delay.

As the AUA 2018 erectile dysfunction guideline notes directly: "Clinicians should discuss the possibility of priapism, transient visual changes, and cardiovascular risk with all men initiating PDE5 inhibitor therapy" [19]. Appetite is conspicuously absent from that disclosure requirement because the evidence base does not support it as a clinically significant concern.

Special Populations

Men Over 65

Older men have higher baseline rates of anorexia of aging, a well-characterized syndrome involving reduced appetite, decreased caloric intake, and progressive sarcopenia [21]. Starting tadalafil in this population may coincide temporally with appetite changes that are age-related rather than drug-related. Clinicians should document appetite and weight at baseline before prescribing in men over 65.

Men With Diabetes

Type 2 diabetes and its treatment (metformin, GLP-1 agonists, SGLT-2 inhibitors) are appetite-active states. Tadalafil is commonly prescribed in diabetic men with ED. Any appetite change in this group requires systematic untangling of concurrent therapies before tadalafil is implicated [17].